We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
-4.87%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$636M
AUM Growth
-$198M
Cap. Flow
-$73.4M
Cap. Flow %
-11.54%
Top 10 Hldgs %
64.01%
Holding
60
New
3
Increased
15
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$26M
2
RGLS
Regulus Therapeutics
RGLS
+$9.9M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$8.8M
4
ANTX icon
AN2 Therapeutics
ANTX
+$5.04M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$4.49M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$49.2M
2
INSM icon
Insmed
INSM
+$19M
3
CYTK icon
Cytokinetics
CYTK
+$13.6M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$9.65M
5
CBIO
Crescent Biopharma
CBIO
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$111M 17.37%
2,880,880
+73,900
+3% +$3.35M
DNTH icon
2
Dianthus Therapeutics
DNTH
$5.68B
$45.2M 7.1%
1,746,667
+366,000
+27% +$8.8M
GPCR icon
3
Structure Therapeutics
GPCR
$3.49B
$44.8M 7.04%
1,140,060
+633,456
+125% +$26M
INSM icon
4
Insmed
INSM
$23.2B
$43.6M 6.85%
650,216
-489,784
-43% -$19M
DYN icon
5
Dyne Therapeutics
DYN
$4.04B
$41.7M 6.55%
1,180,798
-62,147
-5% -$1.81M
AVBP icon
6
ArriVent BioPharma
AVBP
$1.48B
$33.5M 5.26%
1,803,304
-140,532
-7% -$2.51M
VRNA
7
DELISTED
Verona Pharma
VRNA
$27.4M 4.31%
1,895,200
-473,800
-20% -$6.92M
CRBP icon
8
Corbus Pharmaceuticals
CRBP
$170M
$22.1M 3.47%
488,000
+83,000
+20% +$3.49M
CNTA
9
DELISTED
Centessa Pharmaceuticals
CNTA
$21.2M 3.33%
2,345,075
+284,975
+14% +$2.7M
BBIO icon
10
BridgeBio Pharma
BBIO
$16.5B
$17.5M 2.75%
690,000
– –
INSM icon
11
CALL
Insmed
INSM
$23.2B
$16.8M 2.63%
+250,000
New +$9.7M
OCUL icon
12
Ocular Therapeutix
OCUL
$1.86B
$16.6M 2.61%
2,425,000
– –
CATX icon
13
Perspective Therapeutics
CATX
$332M
$15.8M 2.48%
1,580,249
+108,407
+7% +$1.57M
DFTX
14
Definium Therapeutics
DFTX
$5.73B
$15.5M 2.44%
2,153,000
– –
APLS
15
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$13.4M 2.11%
350,000
+150,000
+75% +$6.79M
PRAX icon
16
Praxis Precision Medicines
PRAX
$9.07B
$10.8M 1.69%
260,000
– –
TSHA icon
17
Taysha Gene Therapies
TSHA
$1.59B
$10.2M 1.61%
4,572,222
+1,542,222
+51% +$4.49M
EYPT icon
18
EyePoint Inc
EYPT
$1.02B
$9.51M 1.5%
1,093,503
– –
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$9.29M 1.46%
1,364,400
+739,400
+118% +$4.48M
GOSS icon
20
Gossamer Bio
GOSS
$66.5M
$8.28M 1.3%
9,187,883
– –
VRDN icon
21
Viridian Therapeutics
VRDN
$2.13B
$8.07M 1.27%
620,000
– –
TNYA icon
22
Tenaya Therapeutics
TNYA
$168M
$7.99M 1.26%
2,576,200
-277,800
-10% -$1.15M
RGLS
23
DELISTED
Regulus Therapeutics
RGLS
$7.61M 1.2%
+4,263,701
New +$9.9M
KLRS
24
Kalaris Therapeutics
KLRS
$88.7M
$7.09M 1.11%
426,087
+243,478
+133% +$4.3M
MLYS icon
25
Mineralys Therapeutics
MLYS
$2.35B
$7.02M 1.1%
600,000
+50,000
+9% +$630K
1
2 3

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Octagon Capital Advisors held 60 positions worth $636M, down 24% from $834M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Octagon Capital Advisors withdrew a net $73.4M in Q2 2024, closing 14 positions and reducing 11 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $49.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

Against the trend, Octagon Capital Advisors opened a new position in Regulus Therapeutics worth $7.61M.

  • Octagon Capital Advisors's largest Q2 2024 buy was Regulus Therapeutics: 4,263,701 shares worth $7.61M.
  • Octagon Capital Advisors added most to Structure Therapeutics in Q2 2024, an estimated $26M increase.
  • Octagon Capital Advisors's biggest Q2 2024 reduction was Insmed, cutting an estimated $19M.
  • Octagon Capital Advisors fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $49.2M.
  • Octagon Capital Advisors's ten largest holdings make up 64% of its $636M portfolio in Q2 2024.
  • Octagon Capital Advisors opened 3 new positions and closed 14 in Q2 2024.
  • Octagon Capital Advisors's portfolio value fell 24% quarter-over-quarter to $636M.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.